Press coverage about United Therapeutics Corporation (NASDAQ:UTHR) has trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. United Therapeutics Corporation earned a news sentiment score of 0.08 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.2659663533148 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern’s scoring:

United Therapeutics Corporation (NASDAQ UTHR) opened at 117.57 on Thursday. The company’s 50-day moving average price is $128.37 and its 200 day moving average price is $129.08. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The firm has a market capitalization of $5.11 billion, a price-to-earnings ratio of 13.63 and a beta of 1.52.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). The business had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.42 earnings per share. Equities analysts predict that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

Several equities research analysts have recently commented on UTHR shares. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of United Therapeutics Corporation in a report on Friday, September 8th. BidaskClub downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine raised United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. Finally, UBS AG reaffirmed a “sell” rating and set a $106.00 target price on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Six equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. United Therapeutics Corporation presently has a consensus rating of “Hold” and an average target price of $134.50.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/united-therapeutics-corporation-uthr-getting-somewhat-positive-press-coverage-report-shows/1576826.html.

In other news, CEO Martine A. Rothblatt sold 1,237 shares of the business’s stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $130.92, for a total value of $161,948.04. Following the sale, the chief executive officer now directly owns 1,377 shares in the company, valued at $180,276.84. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher Causey sold 580 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the sale, the director now owns 3,295 shares in the company, valued at $443,111.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,964 shares of company stock worth $3,118,533. Corporate insiders own 7.80% of the company’s stock.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Insider Buying and Selling by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.